FUNDED PROJECTS
We are developing several strategic projects to improve the production of biosimilars
GH Genhelix is implementing its Strategic Plan to enhance the production of monoclonal antibodies, as part of our strong commitment to research, development, and innovation in biosimilar medicines.
This plan is partially funded by the Business Competitiveness Institute of the Regional Government of Castilla y León (ICECYL), with financial support from the European Union, through the European Regional Development Fund (FEDER). The objective is to boost research, technological development, and innovation.
Implementation period: July 2024 – July 2027


PROJECT
PROJECT: DEVELOPMENT OF A FORMULATION BASED ON A MONOCLONAL ANTIBODY FOR THE FUTURE DEVELOPMENT OF A BIOSIMILAR CANDIDATE
File No.: 10/23/LE/0006
PROJECT
PROJECT: PRODUCTION OF A MONOCLONAL ANTIBODY BIOSIMILAR FOR CANCER TREATMENT
File No.: 10/23/LE/0007
PROJECT
PROJECT: DEVELOPMENT OF A PREDICTIVE ARTIFICIAL INTELLIGENCE MODEL INTEGRATED INTO A DIGITAL TWIN